Related Experiment Video
Updated: May 15, 2026
09:28
One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
Metabolomic analysis for first-trimester Down syndrome prediction
Ray O Bahado-Singh1, Ranjit Akolekar, Rupasri Mandal
1Department of Obstetrics and Gynecology, Oakland University -William Beaumont School of Medicine, Royal Oak, MI, USA.
American Journal of Obstetrics and Gynecology
|January 15, 2013
Summary
First-trimester maternal serum metabolomic analysis identified novel biomarkers for predicting Down syndrome (DS). These findings offer new insights into cellular dysfunction associated with DS pregnancies.
Area of Science:
- Biochemistry
- Genetics
- Maternal-Fetal Medicine
Background:
- Down syndrome (DS) is a common chromosomal aneuploidy.
- Early detection of DS is crucial for appropriate management and counseling.
- Current first-trimester screening methods have limitations in sensitivity and specificity.
Purpose of the Study:
- To investigate maternal serum metabolomic profiles in the first trimester of pregnancy.
- To compare metabolite concentrations between pregnancies with DS and euploid controls.
- To identify novel metabolomic markers for DS prediction.
Main Methods:
- A case-control study involving 30 DS pregnancies and 60 controls.
- Maternal serum samples collected between 11+0 and 13+6 weeks of gestation.
- Nuclear magnetic resonance (NMR)-based metabolomic analysis was employed.
Main Results:
- Significant differences in 11 serum metabolites were observed between DS and control groups.
- A combination of 3-hydroxyisovalerate, 3-hydroxybutyrate, and maternal age achieved 51.9% sensitivity at 1.9% false-positive rate for DS detection.
- A multimarker algorithm demonstrated 70% sensitivity at 1.7% false-positive rate.
- Novel markers like 3-hydroxybutyrate (brain growth) and 2-hydroxybutyrate (oxidative stress) were found to be altered.
Conclusions:
- Metabolomic analysis in the first trimester can identify novel biomarkers for fetal DS prediction.
- These findings provide insights into the metabolic and cellular dysfunctions associated with DS.
- Metabolomics holds promise for improving early non-invasive screening for DS.
